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Introduction
A, a 40–42 peptide released from amyloid precursor protein 
(APP) after the sequential cleavages by - and -secretases, is 
recognized as a major culprit of Alzheimer’s disease (AD), the 
most common dementia in people >65 yr of age. Cortical and 
cerebral vascular A deposition is a pathological hallmark in 
AD, in addition to neurofibrillary tangles, chronic inflammation, 
and  neuronal  loss  (Tanzi  and  Bertram,  2005).  Mutations  in   
the genes of APP and presenilin, an essential component of 
-secretase, are found in the early-onset AD. Many risk factors or 
genes associated with the late-onset AD also affect APP protein 
metabolism and A production (Tanzi and Bertram, 2005). Multi-
ple forms of A have been reported, but the prefibrillar and/or 
  soluble oligomers of A, not A deposits, have been recognized to 
be early and key intermediates in AD-related synaptic dysfunction 
(Walsh et al., 2005; Smith et al., 2007; Stefani and Liguri, 2009). 
Mouse brain slices exposed to soluble A oligomers exhibit 
synaptic depression, decrease of the number of spine protrusions 
or synaptic contacts, and impaired long-term potentiation (LTP), 
a form of synaptic plasticity (Roselli et al., 2005; Townsend   
et al., 2006; Nimmrich et al., 2008; Selkoe, 2008; Li et al., 2009). 
In addition, synaptic function is disrupted, and synapses are lost 
in  AD  patients  and  in  animal  models  even  before  amyloid 
plaques are detected (Selkoe, 2002a, 2008; Ashe and Zahs, 
2010). Collectively, these lines of evidence from pathological, 
genetic, biochemical, and physiological studies have indicated a 
crucial role of A in the etiology of AD.
Extensive efforts have been invested to the understanding 
of A production. -secretase, also called BACE1, is essential 
V
PS35, a major component of the retromer com-
plex, is important for endosome-to-Golgi retrieval 
of membrane proteins. Although implicated in 
Alzheimer’s disease (AD), how VPS35 regulates AD-
  associated pathology is unknown. In this paper, we show 
that hemizygous deletion of Vps35 in the Tg2576 mouse 
model of AD led to earlier-onset AD-like phenotypes, 
including cognitive memory deficits, defective long-term 
potentiation,  and  impaired  postsynaptic  glutamatergic 
neurotransmission  in  young  adult  age.  These  deficits 
correlated well with an increase of -amyloid peptide (A) 
level in the mutant hippocampus. We further demonstrate 
that VPS35 is predominantly expressed in pyramidal 
  neurons of young adult hippocampus and interacts with 
BACE1, a protease responsible for A production. Loss 
of VPS35 function in the mouse hippocampus increased 
BACE1 activity. Suppression of VPS35 expression in cul-
ture decreased BACE1 trans-Golgi localization but en-
riched it in endosomes. These results demonstrate an 
essential role for VPS35 in suppression of AD neuropathol-
ogy and in inhibition of BACE1 activation and A produc-
tion by promoting BACE1 endosome-to-Golgi retrieval.
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To elucidate functions of the retromer in AD pathogenesis, 
we  crossed  Tg2576  mice,  a  well-established  AD  mouse 
model that expresses the Swedish mutant form of human APP   
(APPswe) under the control of prion promoter (Chapman et al., 
1999;  Rockenstein  et  al.,  2007),  with  Vps35  mutant  mice. 
Vps35 homozygous mutant mice died during early embryonic 
development,  but  heterozygotes  can  survive  into  adulthood 
with relatively normal behavior, synaptic plasticity, and life 
span. Remarkably, Vps35 heterozygotes;Tg2576 mice dem-
onstrated an earlier onset of AD-like neuropathology, including 
cognitive deficits, impaired glutamatergic transmission, and 
synaptic plasticity, and more A-positive plaques detected in 
the brain. These earlier-onset AD-like phenotypes in the dou-
ble mutant mice suggest that reduced VPS35 levels may exacer-
bate A toxicity. We have investigated underlying mechanisms, 
and our results suggest that VPS35 is required for the endosome-
to-Golgi retrieval of BACE1.
Results
Genetic enhancement and earlier onset  
of Tg2576-associated cognitive deficit  
by loss of VPS35 function
Defective spatial learning and memory are known to be early 
symptoms of AD (Middei et al., 2006; Bizon et al., 2007; Good 
and Hale, 2007; Reed et al., 2010). They are also observed in 
8-mo or older Tg2576 mice that express APPswe (Hsiao et al., 
1996; Chapman et al., 1999; Rockenstein et al., 2007). To study 
the  potential  role  of VPS35  in AD  pathology,  we  generated 
Vps35-deficient mice by using gene-trapping embryonic stem 
(ES) cells from Bay Genomics (see Materials and methods; 
Fig. S1 A). Homozygotes, named Vps35
m/m, were lethal at an 
early embryonic stage (under embryonic day 10 [E10]), but hetero-
zygotes, named Vps35
+/m, whose expression of Vps35 was 
50% of that in wild type (WT; Fig. S1 B), survived to adult-
hood. We crossed Vps35
+/m mice with Tg2576 mice to generate 
Vps35
+/m;Tg2576
+/ mice (Fig. S1 B) and subjected them and 
control littermates (WT, Tg2576
+/ and Vps35
+/m) to the Morris 
water maze test to assess their spatial learning and memory   
(Morris, 1991). In this assay, 3- and 6-mo-old mice were dropped 
into a pool and allowed to swim to locate a submerged platform 
to escape swimming. Tg2576 and Vps35
+/m mice had normal spa-
tial learning and memory response as compared with the age-
matched WT control in viewing their learning the location of the 
submerged platform with repeated testing (Fig. 1). However, the 
double mutant (Tg2576
+/;Vps35
+/m) mice were impaired in this 
task, exhibiting increases of latencies in finding the hidden plat-
form (Fig. 1, A and B) and in pathway length (Fig. 1, C and D) as 
compared with the other three age-matched groups. In addition, 
Tg2576
+/;Vps35
+/m mutant mice performed worse than all other 
groups in probe trials, with less frequency to probe the hidden 
platform (Fig. 1, E and F). Note that no significant difference was 
observed in velocity among the four groups (Fig. 1, G and H). 
Intriguingly, deficits of Tg2576
+/;Vps35
+/m mice in latency and 
distance and platform probe frequency appeared to be severer in 
6-mo-old Tg2576
+/;Vps35
+/m mice compared with those in   
3-mo-old (Fig. 1, A–F). Moreover, double mutant mice at 1–2 mo 
for this event (Hussain et al., 1999; Sinha et al., 1999; Vassar 
et al., 1999, 2009; Yan et al., 1999; Tanzi and Bertram, 2005; 
Bertram and Tanzi, 2008). BACE1 activity is increased in 
postmortem brains of AD patients and in brains of AD mouse 
models (Fukumoto et al., 2002; Yang et al., 2003). Genetic 
ablation of BACE1 in AD animals abolishes A production and 
rescues AD-like phenotypes (Luo et al., 2001; Ohno et al., 2004; 
Laird et al., 2005). BACE1 is a type I transmembrane aspartyl 
protease that has a broad substrate profile, including sialyltrans-
ferase, P-selectin glycoprotein ligand 1, sodium channel, and APP-
like proteins, in addition to APP (Vassar et al., 2009). An in vitro 
study has suggested that the optimal pH of BACE1-mediated APP 
cleavage is pH 5.0, suggesting that an acidic intracellular com-
partment (e.g., endosome) may be more favorable for BACE1 
activation (He et al., 2003). After the cleavage by BACE1, 
-secretase—a multimeric complex that contains presenilins, 
nicastrin,  aph-1,  and  pen2—cleaves  the  membrane-anchored   
C-terminal fragment of APP to release A40/42 (Selkoe and Wolfe, 
2007). Genetic mutations surrounding the -cleavage sites in APP 
can alter the ratio of A40 versus more toxic and amyloidogenic 
A42 (Selkoe and Wolfe, 2007). Mutations in presenilin genes 
in the early-onset AD patients may cause a gain of function 
of -secretase, leading to the increase in A42 to A40 ratio 
(Selkoe, 2002b; Sisodia and St George-Hyslop, 2002). Finally, 
APP can also be cleaved by -secretases, including ADAM10, that 
switch APP processing to a nonamyloidogenic pathway and thus 
reduce the A40/42 production (Esler and Wolfe, 2001).
The  retromer  contains  two  subprotein  complexes:  the 
cargo-selective subcomplex and membrane deformation sub-
complex (Seaman, 2005; Bonifacino and Hurley, 2008). The 
cargo-selective complex is a trimer of vacuolar protein sorting 
(Vps) proteins VPS35, VPS29, and VPS26 that sorts cargos into 
tubules for retrieval to the Golgi apparatus. The membrane de-
formation subcomplex, consisting of sorting nexin dimers 
(Vps5p and Vps17p in yeast and sortin nexins 1/3 or 5/6 in ver-
tebrates), deforms the donor membrane into a tubular profile 
(Seaman, 2005; Bonifacino and Hurley, 2008; van Weering et al., 
2010). The retromer selectively mediates retrograde transport of 
multiple transmembrane proteins from the endosomes to the 
TGN. They include mannose 6-phosphate receptors (Arighi 
et al., 2004), wntless (a receptor for Wnt morphogens; Belenkaya 
et al., 2008; Eaton, 2008; Franch-Marro et al., 2008; Pan et al., 
2008; Port et al., 2008; Yang et al., 2008), Ced1 (a phagocytic 
receptor; Chen et al., 2010), and VPS10 family proteins, such as 
VPS10 in yeast (Iwaki et al., 2006), sortilin, and sortilin-related 
receptor (SorL1 or SorCS1) in vertebrates (Canuel et al., 2008; 
Kim et al., 2010; Okada et al., 2010). Recent studies have sug-
gested that SorL1, also called SorLA and LR11, is an APP-
binding protein and is involved in the pathogenesis of late-onset 
AD (Rogaeva et al., 2007; Willnow et al., 2010). In addition, 
the  cargo-selective retromer proteins VPS35 and VPS26 are 
  decreased in the postmortem hippocampus of AD patients (Small 
et al., 2005). Moreover, VPS26 heterozygote mice show in-
creased levels of endogenous A and impaired LTP (Muhammad 
et al., 2008). These observations suggest that the retromer may 
be involved in the AD pathogenesis. However, the underlying 
mechanisms remain elusive.767 VPS35 prevents A neuropathology • Wen et al.
Acceleration of Tg2576-associated 
synaptic plasticity and glutamatergic 
transmission phenotypes by loss of  
VPS35 function
Tg2576 mice began to show impaired LTP and synaptic trans-
mission in dentate gyrus (DG) at 4–5 mo or older (Jacobsen 
et al., 2006). In the Schaffer collateral (SC) pathway (SC-CA1), 
the deficiency was not detectable until 12–18 mo old (Chapman 
et al., 1999; Fitzjohn et al., 2001). We first examined the basal 
synaptic function at SC-CA1 synapses and DG in hippocampal 
slices of 2–4-mo-old mice. Field excitatory postsynaptic po-
tentials (fEPSPs) were recorded in the CA1 stratum radiatum   
or in the stratum moleculare of the DG by stimulating the   
SC/commissural pathway (for CA1) or the perforant path-
way (for DG) at various intensities. No significant difference in 
fEPSP slopes was detected at the tested stimulus intensities in 
both CA1 and DG areas of Tg2576, Vps35
+/m, and their WT lit-
termate controls (Fig. 2, A and B), suggesting similar strength 
of basal synaptic transmission. However, the fEPSP slopes in 
both CA1 and DG were reduced in Tg2576
+/;Vps35
+/m hippo-
campal slices compared with those of WT, Tg2576, or Vps35
+/m 
mice (Fig. 2, A and B), indicating that synaptic transmission is 
more vulnerable in Tg2576 mice when VPS35 level was reduced. 
Next, we determined whether VPS35 reduction alters synaptic 
plasticity by measuring LTP at the SC-CA1 synapses and DG. 
The posttetanic potentiation of synaptic transmission (within 3 min 
of tetanic stimulation initiation) was similar in CA1 2-mo-old hip-
pocampal slices of all four groups (WT, Vps35
+/m, Tg2576, or 
Vps35
+/m;Tg2576
+/) of mice. However, LTP was reduced in the 
double mutant (Fig. 2, C and D), suggesting impaired synaptic 
plasticity in CA1 in the 2-mo-old Vps35
+/m;Tg2576
+/ hippo-
campus. The impairment worsened in 4-mo-old hippocampal 
slices in the CA1 area (Fig. 2, E and F). Both the posttetanic poten-
tiation and LTP were reduced in 4-mo-old Vps35
+/m;Tg2576
+/ 
CA1 hippocampus (Fig. 2, E and F). Note that posttetanic po-
tentiation and LTP in the CA1 area were apparently normal in 
Tg2576 hippocampal slices at both ages, which is in agreement 
with previous reports that LTP was not impaired until at the age 
of >12 mo old (Chapman et al., 1999; Fitzjohn et al., 2001). In 
addition, LTP at the DG was defective in Tg2576
+/;Vps35
+/m 
mice compared with that in WT, Tg2576
+/, or Vps35
+/m mice 
(Fig. 2, G and H). These results demonstrated that loss of Vps35 
function accelerates the development of synaptic plasticity 
deficits in both CA1 and DG hippocampus of Tg2576 mice.
To investigate possible underlying mechanisms, we stud-
ied the excitatory and inhibitory synaptic transmission in CA1 
pyramidal neurons of 2-mo-old hippocampus (Fig. 3). -Amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
N-methyl d-aspartate (NMDA) receptor-mediated miniature excit-
atory postsynaptic currents (mEPSCs) were recorded in whole-
cell configuration (Fig. 3, A and B). Both amplitudes of AMPA 
and  NMDA  receptor-mediated  mEPSCs  were  significantly  re-
duced in the CA1 pyramidal neurons from Tg2576
+/;Vps35
+/m 
mutant mice as compared with the other three groups (Fig. 3, 
A–D). These results indicate a defective glutamatergic transmis-
sion in postsynaptic regions of the double mutant hippocampus. 
Interestingly, we also observed reductions of the frequencies of 
old did not exhibit significant impairment (unpublished data). 
Thus, these results demonstrate an impaired spatial learning and 
memory in the double mutant mice at the age of 3 and 6 mo old, 
suggesting an earlier onset of Tg2576-associated cognitive defi-
cit by loss of VPS35 function.
Figure 1.  Impaired spatial learning and memory by the Morris water maze 
test in young adult Tg2576
+/;Vps35
+/ mice. (A–H) 3 (A, C, E, and G)- and   
6 (B, D, F, and H)-mo-old Tg2576
+/;Vps35
+/m mice showed increases of 
swimming latency (A and B) and total distance (C and D) in the training ses-
sions but decreases of the platform probe frequency (E and F) in the probe tests 
relative to the age-matched Tg2576
+/, Vps35
+/m, and nontransgenic (WT) 
mice. Although Tg2576
+/;Vps35
+/m showed slightly higher velocity at day 
1–3 sessions, repeated measures ANOVA analysis of the total five sessions 
showed no significant change of the velocity among the four groups in both 
3- and 6-mo-old mice (G and H). Comparing the performance between   
3- and 6-mo-old Tg2576
+/;Vps35
+/m mice, a trend toward longer latency and 
distance was noted in the 6-mo-old mice, but the difference was not significant 
(P > 0.05, using repeated measures ANOVA). However, the platform probe 
frequency was significantly reduced in 6-mo-old Tg2576
+/;Vps35
+/m mice 
as compared with that in 3-mo-old (P < 0.05). Data shown are mean ± SEM, 
and n = 6–10 for each of the genotypes in 3-mo-old mice, whereas n = 5–11 
for each of the genotypes in 6-mo-old mice. *, P < 0.05, with a significant 
difference from the Tg2576
+/, Vps35
+/m, and WT control mice by repeated 
measures ANOVA; 
#, P < 0.05; 
##, P < 0.01, with a significant difference by 
one-way ANOVA followed by the least significant difference test.JCB • VOLUME 195 • NUMBER 5 • 2011   768
double mutant CA1 neurons may be caused by a reduction of 
the  number  of  postsynaptic  glutamatergic  neurons/synapses. 
Consistent with the results in mEPSCs recordings, both amplitudes 
of  evoked  AMPA  receptor-mediated  and  NMDA  receptor- 
mediated EPSCs were lower in CA1 neurons from the double 
mutant slices as compared with the other three groups (Fig. 3 G), 
confirming the deficits of the glutamatergic synaptic transmission 
at the SC-CA1 synapses of young adult Tg2576
+/;Vps35
+/m mice.   
both  AMPA  and  NMDA  receptor-mediated  mEPSCs  in  the 
double mutant CA1 neurons (Fig. 3, A, B, E, and F). This may 
be a result of a defective presynaptic glutamate release or re-
duction of the number of synapses. To further examine whether 
this is a result of a presynaptic defect, paired-pulse facilitation 
was measured. The ratio of paired-pulse facilitation was not 
significantly different among the four groups of mice (Fig. 3 H), 
suggesting that the decreased frequencies of both currents in the 
Figure  2.  Acceleration  of  LTP  deficit  in  the  CA1   
region and the DG in Tg2576
+/ hippocampus by loss of 
Vps35 function. (A and B) Input–output relations gen-
erated by stimulating the SCs and recording in CA1 
stratum radiatum (A) or by stimulating the perforant 
pathway and recording in stratum moleculare of the 
DG (B). The basal transmission in both CA1 (A) and 
DG (B) were similar in aged-matched WT, Tg2576
+/, 
and Vps35
+/m mice but was significantly impaired in 
Tg2576
+/;Vps35
+/m mice. Means ± SEM are shown; 
n = 6–8 for CA1 recordings, and n = 7–9 for DG   
recordings.  *,  P  <  0.05,  using  repeated  measures   
ANOVA. (C) LTP at the SC-CA1 synapses was normal 
in Tg2576
+/ and Vps35
+/m mice but was defective in 
the 2-mo-old Tg2576
+/;Vps35
+/m mice. LTP was in-
duced by one train of 100-Hz stimuli in the SCs. The 
upset shows representative traces of fEPSP recordings 
of responses before and 50 min after high frequency 
stimulation (HFS; arrow). (D) Quantitative analysis of 
data in C. The level of fEPSP potentiation was deter-
mined at a mean of 0–3 min and 50–60 min after 
high frequency stimulation. n = 5–7. (E) Severe LTP 
impairment at the SC-CA1 synapses in the 4-mo-old 
Tg2576
+/;Vps35
+/m mice. (F) Quantitative analysis 
of data in E. n = 5–7. (G) LTP at the DG was normal 
in Tg2576
+/ and Vps35
+/m mice but was defective in 
the 2–4-mo-old Tg2576
+/;Vps35
+/m mice. LTP was 
induced by a strong theta burst stimuli at the perforant 
pathway given at the time indicated by the arrow and 
recorded in the presence of 20 µM bicuculline (see 
Materials and methods). (H) Quantitative analysis of 
data in G. n = 8–11. (D, F, and H) *, P < 0.05; **, 
P < 0.01.769 VPS35 prevents A neuropathology • Wen et al.
the WT control (Fig. 3, A–G), but these reductions were not 
statistically significant. We also examined GABAnergic neuro-
transmission in the four groups of mice by evaluating the min-
iature and evoked inhibitory postsynaptic currents (mIPSCs and 
Note that Tg2576
+/ and Vps35
+/m mutants also showed reductions 
of the amplitudes and frequencies of both AMPA and NMDA 
receptor-mediated mEPSCs and the amplitudes of both evoked 
AMPA and NMDA receptor-mediated EPSCs as compared with 
Figure 3.  Deficit in glutamatergic synaptic transmission in hippocampal CA1 pyramidal neurons of young adult Tg2576
+/;Vps35
+/ mice. (A and B) Rep-
resentative traces of AMPA (A) and NMDA (B) receptor-mediated mEPSCs. All mEPSCs were recorded at a holding potential of 65 mV. NMDA 
receptor-mediated mEPSCs were recorded in Mg
2+-free aCSF (see Materials and methods). Bars, 200 ms, 40 pA. (C and D) Cumulative distribution plots 
(left) and mean amplitude of AMPA receptor-mediated mEPSCs (C, right) and NMDA receptor-mediated mEPSCs (D, right). (E and F) Cumulative frequency 
plots of the interevent interval (left) and quantitative analysis of the frequency of AMPA receptor-mediated mEPSCs (E, right) and NMDA receptor-mediated 
mEPSCs (F, right). (G, bottom) Representative traces of eEPSCs (NMDA [right] and AMPA [left]) and quantitative analysis of evoked AMPA and NMDA 
receptor-mediated EPSC amplitude to stimulus intensity. AMPA and NMDA receptor-mediated EPSCs were recorded at a holding potential of 65 mV 
and +40 mV, respectively. (top) From left to right, the stimulus intensities for each trace were 2, 5, 10, and 30 µA (saturating stimulus). (H) Paired-pulse 
ratio analysis. Data were obtained from whole-cell recordings of CA1 pyramidal neurons from the four indicated groups of mice at the age of 2 mo old, 
including WT, Tg2576
+/, Vps35
+/m, and Tg2576
+/;Vps35
+/m mice. (C–H) Data shown as mean ± SEM were analyzed by one-way ANOVA followed 
by Dunnett’s test (for averaged mEPSC amplitude and frequency and paired-pulse ratio), Kolmogorov–Smirnov test (for mEPSC cumulative histograms), and 
repeated measures ANOVA (for eEPSC amplitude). *, P < 0.05; **, P < 0.01; n = 9–16.JCB • VOLUME 195 • NUMBER 5 • 2011   770
study (Hsiao et al., 1996). Interestingly, there are more, larger 
A  plaques  in  both  6-  and  12-mo-old  Tg2576
+/;Vps35
+/m 
brains in comparison with those in Tg2576 brain samples at re-
spective ages (Fig. 4, A and B). These results demonstrate that 
A  deposits  occurred  in  higher  frequency  and  in  younger 
Vps35
+/m;Tg2576
+/ mice than that in Tg2576 mice.
To investigate mechanisms of how A deposits were in-
creased when VPS35 levels were reduced, we measured A40 
levels in hippocampus and cerebral cortex. Tg2576 mice ex-
press the Swedish mutant form of human APP695 (Hsiao et al., 
1996; Chapman et al., 1999; Rockenstein et al., 2007). ELISA 
analysis of human A40 detected A in homogenates of hippo-
campus and cortex from Tg2576 mice, which is in agreement 
with previous studies (Hsiao et al., 1996; Chapman et al., 1999; 
Rockenstein et al., 2007). No human A40 was detected in WT 
or Vps35
+/m mice (unpublished data). Remarkably, A40 levels 
were significantly higher in 2-mo-old Tg2576
+/;Vps35
+/m hippo-
campus and cerebral cortex as compared with Tg2576 litter-
mate controls (by 30 and 15%, respectively; Fig. 4 C). A similar 
increase was also detected in 4–6-mo-old mice (unpublished 
data). These results indicated that A40 production is enhanced 
eIPSCs, respectively). Neither the frequency nor the amplitude 
of mIPSCs or eIPSCs was altered in the double mutant hippocam-
pus (Fig. S2). Thus, these results demonstrate a decrease of gluta-
matergic, but not GABAnergic, neurotransmission, likely at the 
postsynaptic sites of the young adult double mutant hippocampus.
Increase of A deposits and A40/42 in 
mouse hippocampus and cerebral cortex  
by loss of Vps35 function
The reduced glutamatergic neurotransmission corroborates with 
previous studies and may be caused by A-induced neurotoxic-
ity (Nimmrich et al., 2008; Selkoe, 2008). To determine whether 
A production was increased in the Vps35
+/m;Tg2576
+/ brain, 
we first examined for A deposition by immunohistochemical 
staining. A deposits or plaques were undetectable in brain sec-
tions of Vps35
+/m;Tg2576
+/ mice or the other three genotypes 
at the age of 2–4 mo old (unpublished data). No A deposit was 
observed in brain samples of WT or Vps35
+/m mice as old as 
12 mo (Fig. 4, A and B). A deposits were rare in 6-mo-old 
Tg2576
+/ brain but increased in number and size in 12-mo-old 
samples (Fig. 4, A and B), which is in agreement with a previous 
Figure 4.  Increase of A deposits and A40 in the hippocampus and cortex by loss of VPS35 function. (A and B) Increase of A deposits in 6-mo or older 
Tg2576
+/;Vps35
+/m brain as compared with that of Tg2576
+/ by immunohistochemical staining analysis using anti-6E10 antibody. Images are shown 
in A, and quantification data are presented in B (mean ± SEM; n = 4 for each of the genotypes). *, P < 0.01, with a significant difference from the control 
(Tg2576
+/) by Student’s t test. (C) Increase of human A40 levels in 2-mo-old Tg2576
+/;Vps35
+/m hippocampus and cortex as compared with that of 
Tg2576
+/ mice. (D) Increase of mouse A40 levels in 2-mo-old hippocampus and cortex of Vps35
+/m mice (compared with WT) and Tg2576
+/;Vps35
+/m 
mice (compared with Tg2576
+/). (C and D) Hippocampus and cortex from WT and indicated mutant mice were homogenized with guanidine HCl extrac-
tion buffer, and the homogenates were analyzed by ELISAs for human (C) and mouse (D) A1–40. Data, shown as mean ± SEM, were analyzed by Student’s 
t test. *, P < 0.01. n = 4 for each of the genotypes.771 VPS35 prevents A neuropathology • Wen et al.
the view that increased A levels may be a key detrimental   
factor for the cognitive and LTP deficits associated with the 
AD mice.
Expression of VPS35 in hippocampal and 
layer IV–V cortical pyramidal neurons and 
interaction of VPS35 with BACE1
We further determined in what cells VPS35 is expressed in the 
brain by taking advantage of the Vps35
+/m mice. In these mice, 
the LacZ gene was knocked in in the intron of the Vps35 gene 
(Fig. S1 A); thus, LacZ expression is controlled by the promoter 
of the Vps35 gene. The -gal activity was detectable in many 
layers or regions of the cortex and the hippocampus in neonatal 
mice but became restricted to layers IV–V in the cortex and 
CA2–3 regions of the hippocampus in adult mice (Fig. 5, A and B; 
and Fig. S4). The morphology of these neurons appeared to be   
excitatory pyramidal neurons. To determine whether this is the 
case, we costained the brain section with antibodies against 
VPS35 and CaMKII, a marker for pyramidal neurons. Indeed, 
VPS35 was codistributed with CaMKII in the soma and pro-
cesses of neurons in the cortex and hippocampus (Fig. 5 C).   
when VPS35 levels were reduced, suggesting that VPS35 
negatively regulates A40 production. To test this hypothesis 
further, we examine the effect of Vps35 mutation on A40 
production from endogenous APP on WT and Tg2576 back-
ground. Indeed, ELISA analyses of mouse A40 revealed an 
increase in the hippocampus and cerebral cortex of 2-mo-old 
Vps35
+/m compared with WT (Fig. 4 D). Moreover, mouse 
A40 was also higher in the 2-mo-old Tg2576
+/;Vps35
+/m 
hippocampus and cerebral cortex than that of Tg2576 sam-
ples (Fig. 4 D). Elevated mouse A40 level was also detected 
in the hippocampus and cortex of 4–6-mo-old Vps35
+/m mice 
(compared with the WT controls) and Tg2576
+/;Vps35
+/m 
mutant  mice  (compared  with  the  Tg2576
+/  mice;  unpub-
lished data). These results corroborate that VPS35 negatively 
regulates A40 production. In addition to A40, levels of human 
and mouse A42 were also increased by Vps35
+/m mutation 
(Fig. S3 A and not depicted). However, the ratio of A40/
A42 was not changed (Fig. S3 B), implicating that changes 
in  VPS35  levels  may  not  modulate  the  specificity  of  the   
-secretase cleavage of APP. Together, these data suggest 
that VPS35 negatively regulates A production and support 
Figure 5.  VPS35 expression in pyramidal neurons of hippocampus and cortex. (A and B) Detection of enzymatic LacZ activity in 2-mo-old WT (Vps35
+/+) 
and Vps35
+/m cortex (A) and hippocampus (B). LacZ activity was only detected in Vps35
+/m but not WT and was largely expressed in layer IV–V cortical 
neurons and CA1–3 hippocampus. Layers I–VI in cortex and DG and CA1–3 in hippocampus are indicated. Bars, 200 µm. (C and D) Immunofluorescence 
staining analysis of VPS35 protein distribution in pyramidal neurons of cortex and hippocampus from adult mouse brain. Confocal images of coimmuno-
staining analysis of VPS35 with CaMKII (C) and MAP2, parvalbumin (PV), and GAD67-GFP (D) are shown with their respective enlarged images of the 
boxed regions (C). Bars, 20 µm.JCB • VOLUME 195 • NUMBER 5 • 2011   772
These  results  support  an  interaction  between  VPS35  and 
BACE1 in vitro and in vivo and reveal a BACE1-binding site in 
VPS35 (the amino acids of 390–606; Fig. 6 F).
Increase of BACE1 in endosomal 
compartments in Vps35-deficient  
NLT cells and neurons
To investigate the potential function of VPS35–BACE1 inter-
action, we examined whether BACE1 subcellular distribution is 
regulated by VPS35. To this end, we generated small hairpin 
RNAs (shRNAs) and microRNAs (miRNAs) to suppress VPS35 
expression. Transfection of shRNA-Vps35 or miRNA-Vps35, 
but not control (a scrambled miRNA), inhibited expression of 
cotransfected  Flag-Vps35  in  HEK293  cells  (Fig.  S5 A)  and   
endogenous VPS35 in NLT cells (Fig. S5 B). HA-tagged BACE1 
was present in perinuclear vesicles, close to Golgi apparatus, in 
control NLT cells (Fig. 7 A). In cells whose VPS35 expression 
was suppressed, BACE1 punctae were enlarged in size and no 
longer confined to the Golgi apparatus (Fig. 7 A). Instead, 
BACE1 became colocalized with LAMP1, a marker of late   
endosomes/lysosomes (Fig. 7, A and C), suggesting that VSP35 
is critical for BACE1 to be localized in the Golgi apparatus, and, 
when VPS35 levels were lower, BACE1 is relocated. To further 
In contrast, the levels of VPS35 were low in interneurons, i.e., 
neurons labeled by parvalbumin in WT mice or GFP in GAD67-
GFP mice (Fig. 5, C and D). Subcellularly, VPS35 appeared to be 
enriched in dendrites that were labeled by MAP2, a dendritic 
marker in both the cortex and the CA1–3 regions of the hippo-
campus (Fig. 5 D).
A40/42  production  requires  BACE1.  Thus,  we  deter-
mined whether VPS35 associates with BACE1 in neurons by 
coimmunostaining analysis. BACE1 and VPS35 were colocal-
ized largely at perinuclear compartments in NLT cells, a cell 
line derived from GnRH neurons, and in mouse cortical neurons 
(Fig. 6, A and B). These results implicate a potential interaction 
between VPS35 and BACE1 in neurons. We further tested this 
view by coimmunoprecipitation analyses of mouse brain lysates, 
in which VPS35 was detected in BACE1-immunoprecipitated 
complexes (Fig. 6 C). We then mapped the interaction domain 
by in vitro GST pull-down assay and coimmunoprecipitation 
analysis of lysates from HEK293 cells expressing BACE1 and 
mutant VPS35. BACE1 displayed seemingly greater binding 
affinity for full-length VPS35 (VPS35
Fl) as compared with that 
of VPS35
1–390 in in vitro GST pull-down assays (Fig. 6, D and F). 
In coimmunoprecipitation analysis, however, VPS35
1–606 showed 
stronger association than that of the VPS35
Fl (Fig. 6, E and F). 
Figure 6.  VPS35–BACE1 interaction in vitro, in culture, 
and in mouse brain. (A) Coimmunostaining analysis of 
exogenous BACE1 with endogenous Vps35 in NLT cells 
transfected with BACE1-HA. Closed arrows indicate their 
colocalization, and open arrows indicate BACE1-HA–
negative cells. (B) Coimmunostaining analysis of endoge-
nous BACE1 with Vps35 in primary cultured mouse cortical 
neurons  (DIV3).  Arrows  indicate  their  colocalization.   
(A and B) Bars, 20 µm. (C) Coimmunoprecipitation (IP) 
analysis of VPS35–BACE1 protein complexes in homoge-
nates of mouse brain. IB, immunoblotted; NS, nonspecific. 
(D) In vitro VPS35–BACE1 interaction revealed by GST 
pull-down assay. HEK293 cells expressing BACE1-HA were 
lysed, and resulting lysates were incubated with indicated 
GST fusion proteins (5 µg) immobilized on beads. Bound 
proteins were probed with anti-HA and -GST antibodies. 
(E)  Coimmunoprecipitation  analysis  of  VPS35–BACE1 
protein  complexes  in  lysates  of  HEK293  cells  express-
ing  the  indicated  plasmids.  HEK293  cell  lysates  were 
incubated with anti-HA antibodies to immunoprecipitate 
BACE1 complexes, which were resolved on SDS-PAGE 
and immunoblotted with antibodies against Flag. BACE1 
and VPS35 in lysates were revealed by immunoblotting 
with anti-HA and -Flag antibodies, respectively. (F) Illustra-
tion of VPS35 structure, its binding partners, and mutant 
VPS35 proteins and a summary of the data for VPS35–
BACE1 interaction. n/a, not analyzed.773 VPS35 prevents A neuropathology • Wen et al.
were observed in NLT cells expressing miRNA-Vps35 (unpub-
lished data). In agreement with this, BACE1-Rab7 colocaliza-
tion was increased in neurons of Vps35
+/m mice (Fig. 7, D and E). 
Collectively, these results demonstrate that VPS35 is required 
for the retrieval of BACE1 from endosomes to the Golgi appa-
ratus in both NLT and hippocampal neurons (Fig. 7 F).
study this phenomenon, we coexpressed various markers for 
early, late, and recycling endosomes (GFP-Rab5, Rab7, and 
Rab11, respectively). As shown in Fig. 7 (B and C), suppression 
of VPS35  expression  increased  BACE1  localization  in  both 
Rab5- and Rab7-positive endosomal compartments but reduced 
BACE1 in Rab11-labeled recycling endosomes. Similar effects 
Figure 7.  Increase of BACE1 localization in endosomal compartments in NLT cells suppressing Vps35 expression and in Vps35
+/ neurons. (A) Co-
immunostaining analysis of exogenous BACE1 with endogenous Vps35, GM130, and LAMP1 in NLT cells transfected with BACE1-HA with control or 
shRNA-Vps35. MOCK indicates control shRNA. (B) Coimmunostaining analysis of BACE1 with GFP-Rab5/7/11 in NLT cells coexpressing BACE1-HA and 
GFP-Rab5/7/11 with control or shRNA-Vps35. (A and B) Amplified images were included (indicated in the insets). (C) Quantification analysis of data from 
A and B using ImageJ. The colocalization index of BACE1 with the indicated markers (LAMP1 and Rab-5/7/11) was determined by the measurement of 
overlapped signal (yellow fluorescence) over total BACE1 signal. Data are shown as mean ± SEM (n = 5). *, P < 0.01 compared with control shRNA (Ctr 
shRNA) cells. (D) Coimmunostaining analysis of endogenous BACE1 with Rab7 in primary cortical neurons from WT and Vps35
+/m mouse (E18 and DIV3). 
Amplified images are indicated in the insets. (E) Quantification analysis of data from D using ImageJ. The colocalization index of BACE1 with Rab7 was 
determined by the measurement of overlapped signal (yellow fluorescence) over total BACE1 signal. Data are shown as mean ± SEM (n = 5). *, P < 0.01 
compared with WT neurons. (F) Illustration of the working model for Vps35 in BACE1 endosomal-to-Golgi retrieval. Bars, 20 µm.JCB • VOLUME 195 • NUMBER 5 • 2011   774
hippocampus  compared  with  Tg2576  alone  (Fig.  8,  B–F). 
However, C83 levels were not consistently altered by Vps35 
mutation (Fig. 8, C and E), suggesting that Vps35 mutation 
had no or weak effect, if there is any, on -secretase activity. 
Together, these results indicate that loss of Vps35 promotes 
BACE1-mediated cleavage of APP or APPswe, thereby in-
creasing A production.
We then measured the BACE1 activity directly by an   
in vitro assay in both hippocampus and cortex from the four dif-
ferent groups at the age of 2 mo old (Fig. 8 G). Approximately 
25  and  10%  increases  of  BACE1  activity  were  found  in 
Tg2576
+/ hippocampus and cortex, respectively (compared 
with the WT control; Fig. 8 G), which is in line with previous 
studies (Fukumoto et al., 2002; Yang et al., 2003). Interest-
ingly, Vps35
+/m hippocampus and cortex exhibited significant 
increases of BACE1 activity by 50 and 20%, respectively, 
as compared with that of WT controls (Fig. 8 G). The double 
mutant showed a further increase of BACE1 activity in both 
hippocampus and cortex as compared with the single mutant 
mice (Fig. 8 G). Note that the increase of BACE1 activity in 
the mutant hippocampus was more dramatic as compared with 
Increased BACE1-mediated cleavage of 
APP and BACE1 activity in VPS35  
mutant mice
The aforementioned results demonstrate that VPS35 regulates 
BACE1 subcellular distribution. To determine whether these 
effects have any functional consequences, we measured BACE1 
activity in Vps35
+/m hippocampus and cortex. BACE1 activity 
was  first  determined  by  Western  blot  analysis  of  BACE1- 
mediated cleavage fragments (CTF or C99 and sAPP) of 
APP (Fig. 8 A). Using 6E10, a monoclonal antibody that spe-
cifically recognizes the N-terminal 1–16 amino acid residues 
of human C99 and A40/42, CTF or C99 was not detected in 
WT or Vps35
+/m but was in Tg2576 hippocampus and cortex 
(Fig.  8  B).  Interestingly,  C99  levels  were  increased  in 
Tg2576
+/;Vps35
+/m (Fig. 8, B–D), suggesting an increased 
activity of BACE1 when Vps35 was deficient. To test this 
hypothesis further, samples were analyzed by Western blots   
using a polyclonal antibody that specifically recognizes the 
sAPP and the 6687 polyclonal antibody that recognizes both 
C99 and C83 (an -secretase cleavage product; Fig. 8 A). Again, 
levels of sAPP and C99 were increased in Tg2576
+/;Vps35
+/m  
Figure 8.  Increase of BACE1-mediated cleavage of APP 
and BACE1 activity in young adult Tg2576
+/;Vps35
+/m 
hippocampus. (A) Illustration of APP structure and its cleav-
age sites. The epitopes for the antibodies (sAPP, 6E10, 
and 6687) and the cleavage fragments (sAPP, CTF/
C99, and CTF/C83) are indicated. (B and C) Western 
blot analysis of C99 and sAPP BACE1-mediated APP 
cleavage  products  using  the  indicated  antibodies.  Ho-
mogenates  of  cortex  and  hippocampus  from  2-mo-old 
WT,  Vps35
+/m,  Tg2576
+/,  and  Tg2576
+/;Vps35
+/m 
mice were subjected to Western blot analysis (16% Tri-
cine  SDS-PAGE;  see  Materials  and  methods).  The  full 
length (FL) of APP, the C99, sAPP, and C88 is indicated 
by arrows. APP6687, but not 6E10, antibody also detected 
C83  (indicated  by  the  open  arrow),  an  -secretase– 
mediated APP cleavage product. Equal amounts of homog-
enates (50 µg of protein) were loaded and revealed by 
immunoblot (IB) using anti–-actin antibody. (D–F) Quanti-
fication analysis of C99 (D), C83 (E), and sAPP (F) cleav-
age products, in which three different experiments were 
quantified, and data were shown as mean ± SEM. *, P <   
0.05, compared with Tg2576
+/. (G) In vitro BACE1 
activity measured by a BACE1 assay kit purchased from 
Abcam. The hippocampal and cortical homogenates from 
2-mo-old WT and the indicated mutant mice were pre-
pared for the in vitro BACE1 activity assay (see Materials 
and methods). The data were quantified from three to four 
different experiments and shown as mean ± SEM. *, P < 
0.01 compared with WT control; **, P < 0.01 compared 
with Tg2576
+/.775 VPS35 prevents A neuropathology • Wen et al.
it cannot be excluded in an A-independent mechanism that may 
also contribute to the loss of synapses and synaptic activity in 
the double mutant hippocampus. Note that the hippocampus of 
Vps35
+/m in the WT background also exhibits an increase of A 
levels, a decrease of synaptic activity (both NMDA and AMPA 
currents), and a loss of synapses (decrease of frequency of 
mEPSCs) but without obvious defects on cognitive learning 
and memory or LTP (Figs. 1–4). These observations suggest 
that it may need to reach a threshold level of A (as does the 
double mutant but not Vps35
+/m) or an A-independent factor to 
induce the loss of synaptic plasticity and cognitive deficit. It is 
possible that loss of Vps35 function may predispose neurons to 
a greater A toxicity and may facilitate disease progression in 
an age-dependent manner.
Genetic, biochemical, animal, and human studies have all 
pointed to A peptide to be a major culprit in AD pathogenesis 
(Tanzi and Bertram, 2005; Selkoe, 2008). Identification of mu-
tations in APP and presenilins in the early-onset AD provides a 
strong genetic support for the amyloid hypothesis (Hardy and 
Selkoe, 2002). Many risky factors associated with the late-onset 
AD also affect APP metabolism and increase A production, 
which include ApoE4 and SorL1 (Rogaeva et al., 2007; Willnow 
et al., 2010). Interestingly, SorL1 is a Vps10 family member in 
the retromer complex that interacts with APP and VPS35, and 
the interaction of SorL1 with VPS35 is necessary for SorL1 to 
control APP metabolism (Lane et al., 2010). Our results, in line 
with these observations, support the view for the dysfunction of 
VPS35-containing retromer as a risk factor for AD. This view is 
also supported by the observation that VPS35 is decreased in 
the postmortem hippocampus of AD patients (Small et al., 2005). 
Of interest to note is that loss of function of SorCS1, a SorL1 
family protein and a risk factor for type 2 diabetes, also leads to 
an increase of A and a decrease of VPS35 levels (Lane et al., 
2010), raising a possibility for the involvement of Vps35 ret-
romer in regulating insulin sensitivity in addition to APP me-
tabolism. Also of interest to note is that mutation in Vps35 gene 
has recently been identified in patients of late-onset Parkinson’s 
disease (PD; Vilariño-Güell et al., 2011; Zimprich et al., 2011), 
indicating the involvement of Vps35 in the pathogenesis of PD. 
Thus, these observations together with our results support the 
view for the impairment of Vps35 retromer as a general risky 
factor for a growing number of chronic degenerative disorders, 
including AD and PD.
How  does  retromer  regulate  A  production?  Our  data 
suggest that BACE1 activation in the Vps35
+/m hippocampus 
may be essential for this event. VPS35 is codistributed with 
BACE1 in hippocampus (not depicted) and in cultured cells 
(Fig. 6). Loss of VPS35 function in mouse hippocampus increases 
BACE1 activity (Fig. 8). Depletion of Vps35 expression in cul-
ture increases BACE1 localization to the endosomal compartments 
(Fig. 7), an acidic environment favoring BACE1 activation. 
Although our experiments have pointed to the importance of 
endosomal BACE1 cleavage of APP, it remains to be further 
investigated whether the activity of Golgi/endosome-associated 
BACE1 is altered by loss of Vps35 function, in which subcellu-
larly A is produced in Vps35-deficient neurons, and whether 
APP and APPswe protein trafficking is differentially regulated 
that in the cortex (Fig. 8 G). Thus, these results support the 
notion that loss of VPS35 function leads to an increase of 
BACE1 activity and thus A production.
Discussion
VPS35, a major component in the cargo recognition complex of 
retromer, plays an important role in endosome-to-Golgi retrieval 
of multiple membrane proteins. Although retromer is implicated 
in the pathogenesis of late-onset AD, the function of VPS35 in 
AD pathology and the underlying molecular mechanisms remain 
largely unclear. In this study, we showed that Vps35 regulates 
BACE1 cellular trafficking, and loss of Vps35 function leads to 
an increase of BACE1 activity and A levels (Figs. 4–8). Tg2576 
mice with reduced VPS35 expression exhibit an earlier onset of 
AD-like phenotypes, including cognitive memory deficits, re-
duced LTP, and decreased glutamatergic neurotransmission in 
2-mo-old mice (Figs. 1–3). We also demonstrated that knocking 
down VPS35 expression in cultured cells increased BACE1   
localization to the endosomal compartments where the BACE1 
cleavage of APP is favored, providing a mechanism underlying 
VPS35/retromer regulation of BACE1 activation (Fig. 7 F). 
Moreover, we demonstrated that VPS35 is highly expressed in 
pyramidal neurons in young adult CA1–3 hippocampus, inter-
acts with BACE1, and regulates BACE1 distribution. Collec-
tively, our work provides strong evidence for VPS35 to be a 
crucial component in BACE1 trafficking, APP metabolism, and 
hippocampal neuronal synaptic function and establishes a novel 
mouse model in which impaired retromer function leads to al-
tered BACE1 activation and A production, thus facilitating AD 
disease progression in an age-dependent manner.
Many animal models have been developed for the study 
of pathological features of AD, including Tg2576, a transgenic 
line expressing Swedish mutant APP. Tg2576 mice normally 
develop AD-like phenotypes, including cognitive deficits and 
A deposits, at the age of at least 10 mo or older (Chapman 
et al., 1999; Middei et al., 2006; Bizon et al., 2007). Remark-
ably,  the  double  mutant  mice  (Vps35
+/m;Tg2576
+/)  develop 
AD-like phenotypes at the age of 2/3 mo old, featured with cog-
nitive memory deficit, synaptic plasticity (LTP) impairments, 
decrease of glutamatergic transmissions, and increase of A 
levels (Figs. 1–4). These observations demonstrate that VPS35 
plays an important role in the control of the early onset of AD 
neuropathology, contributing to the growing body of evidence 
for the retromer-sorting pathway in the pathogenesis of AD.
The  double  mutant  mice  (Vps35
+/m;Tg2576
+/)  display 
impairments in NMDA and AMPA receptor-mediated synaptic 
transmission and synaptic plasticity (LTP) but not GABAergic 
transmission. These defects may be caused by a loss of excit-
atory synapses and/or a decrease of glutamatergic synaptic ac-
tivity, which contribute to the progressive cognitive decline in 
the mutant mice. Our data corroborate with the view that the 
decreased NMDA and AMPA currents may be induced by 
the increase of soluble A oligomers, but not A deposits, in 
the double mutant brain (Nimmrich et al., 2008; Selkoe, 2008), 
as these deficits occur as early as 2 mo old, whereas A deposi-
tion is detectable at the age of 6 mo and older. On the other hand, JCB • VOLUME 195 • NUMBER 5 • 2011   776
Before hidden-platform training, mice were given one pretraining trial in 
which no platform was placed in the pool, and mice had to swim in the 
pool for 60 s. Mice that had less motivation for swimming were excluded 
from the experiment. The day after pretraining, mice were trained in the 
circular water maze. For hidden-platform training, the escape platform 
(10 cm in diameter) was submerged 1.0 cm beneath the water surface. 
The platform location remained the same throughout hidden-platform train-
ing, but the drop location varied semirandomly between trials. Mice re-
ceived one training session for a consecutive 5 d. Each session consisted 
of four trials with a 1-min intertrial interval. The maximum time allowed per 
trial in this task was 120 s. If a mouse did not find the platform, it was 
gently guided to it and allowed to sit on it for 30 s before being removed 
to its retaining cage. The mean latency and distance moved were calcu-
lated for each mouse by averaging the latency and distance across all 
four trials. For probe trials, the platform was removed, and mice were   
allowed to swim for 60 s before they were removed. The drop location   
for probe trials was 180° from where the platform was located during   
hidden-platform training. The swimming behavior was monitored by cam-
era  (WV-BP334;  Panasonic),  and  images  and  swimming  paths  were 
stored in a computer and analyzed automatically by using EthoVision soft-
ware (version 7.0; Noldus Information Technology).
The spontaneous locomotor activity in an open field was measured 
as previously described (Wen et al., 2010). The mice were transferred to 
the testing room and acclimated for at least 3 d before testing. Mice were 
then placed in an open field chamber (27.9 × 27.9 cm) that uses a series 
of horizontally mounted photobeams to monitor animal movements (Med 
Associates Inc) for 10 min. Ambulatory activity was measured as total hori-
zontal photobeam breaks (horizontal activity). The apparatus was cleaned 
with 70% alcohol between testing of each mouse. Total movements (ambu-
lations) in the outer periphery and center of the open field were recorded 
for further data analysis.
Electrophysiological recording
Brain slices were prepared using standard procedures (Wen et al., 2010). 
In brief, transverse hippocampal slices (0.40 mm) were prepared from WT 
and mutant littermates using a Vibroslice (VT 1000S; Leica) in an ice-cold 
solution containing 64 mM NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 10 mM 
MgSO4, 0.5 mM CaCl2, 26 mM NaHCO3, 10 mM glucose, and 120 mM 
sucrose. Slices were allowed to recover for 30 min at 34°C and then at 
room temperature (25 ± 1°C) for an additional 2–8 h in artificial cerebro-
spinal fluid (aCSF) containing 126 mM NaCl, 2.5 mM KCl, 1.25 mM 
NaH2PO4, 2 mM MgSO4, 2 mM CaCl2, 26 mM NaHCO3, and 10 mM 
glucose. Slices were transferred to the recording chamber and superfused 
with aCSF (2 ml/min) at 34°. All solutions were saturated with 95% O2/5% 
CO2 (volume/volume). fEPSPs were evoked in the CA1 stratum radiatum or 
in the stratum moleculare of the DG by stimulating the SCs/commissural 
pathway (for CA1) or the perforant pathway (for DG) with a two-concentri-
cal bipolar stimulating electrode (25-mm pole separation; FHC, Inc) and 
were recorded in current-clamp by the Axon MultiClamp 700B amplifier 
(Molecular Devices) with aCSF-filled glass pipettes (2–5 MΩ). Test stimuli 
consisted of monophasic 100-µs pulses of constant currents (with intensity 
adjusted to produce 25% of the maximum response) at a frequency of 
0.0167 Hz. The strength of synaptic transmission was determined by mea-
suring the initial (10–60% rising phase) slope of fEPSPs. LTP in the CA1 
area was induced by one train of 100-Hz stimuli with the same intensity of 
the test stimulus, and a cut was made between CA1 and CA3 in hippocam-
pal slices to prevent the propagation of epileptiform activity. For LTP experi-
ments in the DG, slices were incubated in 20 µM bicuculline to block 
GABAA-mediated inhibition, and LTP was induced by the theta burst stimu-
lation (six pulses at 250 Hz, with bursts delivered at a frequency of 5 Hz, 
and six trains of bursts delivered six times, with 20 s between trains).
For whole-cell patch-clamp recordings, stratum pyramidal of CA1 
neurons were visualized using an infrared differential interference contrast 
microscope with a 40× water immersion lens (Axioskop 2 Fs Plus; Carl 
Zeiss) and an infrared-sensitive charge-coupled device camera. All experi-
ments were conducted on neurons located within the cell-dense band CA1 
region and bearing pyramidal-shaped cell bodies with single apical den-
drites. Whole-cell patch-clamp recordings were performed using an ampli-
fier (Axon Multiclamp 700B) and digitized by pClamp software (version 
9.2; Molecular Devices). Both mEPSCs and mIPSCs were recorded at a 
holding potential of 65 mV. For mEPSC recording, glass pipettes were 
filled with the solution containing 120 mM K-gluconate, 20 mM KCl, 10 mM 
Hepes, 0.1 mM EGTA, 2 mM MgCl2, 10 mM sodium phosphocreatine, 
0.2  mM  leupeptin,  4  mM  Mg-ATP,  and  0.3  mM  Na-GTP,  pH  7.3   
(280 mOsm). K-gluconate in the pipette solution was substituted with 140 mM 
by VPS35. It is likely that, in addition to BACE1 activation, 
altered APP metabolism also contributes to the elevated A 
levels in Vps35-deficient neurons. The observation that SorL1 
interaction with VPS35 is required for SorL1 to control APP 
metabolism (Willnow et al., 2010) supports this view. The in-
creased A levels in both Vps35
+/m and Vps35
+/m;Tg2576 mu-
tant mice (Fig. 4, C and D) suggest a role for VPS35 not only in 
regulating WT APP, but also APPswe, metabolism. However, 
mechanisms underlying VPS35 regulation of APPswe and WT 
APP may be different, as it is reported that APPswe exhibits a 
much higher affinity to BACE1 as compared with the WT APP, 
and APPswe may be cleaved by BACE1 at the TGN, whereas 
WT  APP  may  be  cleaved  at  the  endosome  compartments 
(Haass et al., 1995; Selkoe et al., 1996; Thinakaran and Koo, 
2008). Collectively, the data presented in this manuscript sug-
gest an important function of VPS35 in suppression of BACE1 
activation and A production, thus preventing AD-associated 
memory  cognitive  deficits  and  impairment  of  glutamatergic 
synaptic activity.
Materials and methods
Reagents and animals
Rabbit polyclonal anti-VPS35 antibody was generated using the antigen of 
GST-VPS35D1 fusion protein, as previously described (Small et al., 2005). 
Rabbit polyclonal anti-APP6678 (Invitrogen) and anti-BACE1 (Millipore) 
antibodies and monoclonal anti-APP (6E10; Covance), BACE1 (Millipore), 
CaMKII (Clone 6G9; Millipore), parvalbumin (PV235; Swant, Inc.), and 
MAP2 (Millipore) antibodies were used. Other chemicals and reagents 
used in this study were of analytical grade.
Vps35 mutant mice were generated by injection of mutant ES cells 
obtained from Bay Genomics. In brief, ES cells that contain the Vps35 
gene disrupted by gene trapping using the pGT1TMpt vector (Fig. S1 A) 
were obtained from Bay Genomics. ES cell clones were transferred into 
mouse  blastocysts.  Chimeras  generated  from  ES  cells  were  crossed  to 
C57/BL6 mice for more than six generations, and the resulting heterozy-
gous animals were crossed to Tg2576 mice (purchased from Taconic) to 
produce four different genotyped mice (WT, Tg2576
+/, Vps35
+/m, and 
Tg2576
+/;Vps35
+/m). Mice were maintained on a standard rodent diet 
(Teklad S-2335; Harlan Laboratories, Inc.). Control littermates (WT, Vps35
+/m, 
and Tg2576
+/) and Tg2576
+/;Vps35
+/m were processed in parallel for 
each experiment. Tg2576 and Vps35 mutations were confirmed by geno-
typing using PCR (Fig. S1 B). All experimental procedures were approved 
by the Animal Subjects Committee at the Georgia Health Sciences Univer-
sity, according to National Institutes of Health guidelines.
Expression vectors
The cDNAs encoding Vps35 were amplified by PCR and subcloned into 
mammalian expression vectors downstream of a signal peptide and a Flag 
epitope tag (MDYKDDDDKGP) and under control of the cytomegalovirus 
promoter (Ren et al., 2004; Xie et al., 2005). The shRNA-Vps35 expres-
sion vector was generated by the pSuper vector system, and the miRNA-
Vps35 expression vector was generated by the BLOCK-iT Lentiviral miR 
RNAi expression system (Invitrogen) according to the manufacturer’s instruc-
tions (Zhu et al., 2007). The plasmid encoding BACE1-HA was generated 
by insertion of the HA tag to the C terminus of the human BACE1 in the 
pcDNA3 vector, as previously described (Hu et al., 2010). The plasmids 
encoding GFP-Rab5, GFP-Rab7, and GFP-Rab11 were obtained from Add-
gene and deposited by R. Pagano (Mayo Clinic, Rochester, MN). The au-
thenticity of all constructs was verified by DNA sequencing.
Behavior tests
Behavioral analysis was performed with 1–2-, 3-, and 6-mo old mice by 
investigators unaware of their genotype. The Morris water maze testing 
was performed as previously described (Morris, 1991). The maze con-
sisted of a pool (120 cm in diameter) filled with water (22 ± 1°C) made 
opaque white with bright white food color (1498A; AmeriColor), and the 
pool was located in a room surrounded by distinct extra maze cues.   777 VPS35 prevents A neuropathology • Wen et al.
polyornithine-coated coverslips from cortical tissues of E18–19 mouse 
embryos, as previously described (Xie et al., 2005). Neurons were grown 
overnight in plating medium (5% FBS and 1× B27 supplemented with 
100× l-glutamine in Neurobasal medium [Invitrogen]). Starting at day in 
vitro 2 (DIV2), cultures were maintained in conditioned medium with half-
feed changes of neuronal feed (1× B27 in Neurobasal medium) every 3 d. 
For transfection, NLT cells were plated at a density of 10
6 cells per 10-cm 
culture dish and allowed to grow for 12 h before transfection using Lipo-
fectamine. 36 h after transfection, cells were subjected to immunostaining 
analysis.  The  calcium  phosphate  method  was  used  for  transfection  of 
HEK293 cells. 48 h after transfection, cells were lysed in modified radioim-
munoprecipitation assay buffer (50 mM Tris-HCl, pH 7.4, 150 mM sodium 
chloride, 1% NP-40, 0.25% sodium deoxycholate, and proteinase inhibi-
tors).  Lysates  and  medium  were  subjected  to  immunoblotting  analyses. 
Neurons were transfected with various constructs at either DIV4 or 7 using 
the calcium phosphate method followed by immunocytochemistry 96 h 
after transfection, as previously described (Zhu et al., 2007).
Statistical analysis
All data were expressed as mean ± SEM. All data were analyzed by one-
way or repeated measures analysis of variance (ANOVA; SPSS16) followed 
by the least significant difference or Dunnett’s test for post hoc comparisons 
or an independent sample t test unless otherwise specified. The signifi-
cance level was set at P < 0.05.
Online supplemental material
Fig. S1 demonstrates the generation of Vps35
+/m and Tg2576
+/;Vps35
+/m 
mutant mice. Fig. S2 depicts the normal inhibitory synaptic transmission in 
hippocampal CA1 pyramidal neurons of Tg2576
+/;Vps35
+/m mice. Fig. S3 
shows an increase of A42 in young adult Tg2576
+/;Vps35
+/m hippocam-
pus without a change of the ratio of A40 versus A42 in the mutant mice.   
Fig. S4 demonstrates an age-dependent reduction of Vps35 expression in 
CA1 and cortical neurons. Fig. S5 shows the suppression of Vps35 expression 
by both shRNA and miRNA-Vps35. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201105109/DC1.
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-Gal detection, immunofluorescence staining, and confocal  
imaging analysis
Brain sections derived from adult mice (WT, heterozygotes, and Tg2576
+/; 
Vps35
+/m) were fixed with 0.5% glutaraldehyde and incubated with X-gal 
solution (2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, and 0.1% X-gal) in the dark at 37°C for 8 h, as previously 
described (Lee et al., 2010; Zhou et al., 2010). For immunohistochemi-
cal staining, age-matched littermates were perfused transcardially with 
4% PFA in 0.1 M PBS, and brain tissues were postfixed at 4°C for 24 h. 
Paraffin sections (10 µm in thickness) were subjected to the immunohis-
tochemical staining analysis of the A plaques (by 6E10 antibody). The 
staining signal was revealed by reaction with an HRP system (DAB; Invitro-
gen). Transfected cells on the coverslips were fixed with 4% PFA and 4% 
sucrose at room temperature for 45 min, permeabilized in 0.15% Triton   
X-100 for 8 min, and then subjected to coimmunostaining analysis using 
indicated antibodies, as previously described (Zhu et al., 2007). Con-
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